THE SAMUEL WAXMAN Cancer Research Foundation (SWCRF) will present the 2018 Daid T. Workman Memorial Award to Craig B. Thompson, MD, President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center, at its Breakthroughs Scientific Symposium in late April. The event brings together SWCRF grantees, scientific leaders, and stakeholders to mark the annual evaluation of SWCRF-funded research programs.
Craig B. Thompson, MD
This biennial recognition and 2-year grant is bestowed to scientists who develop novel therapies for poorly treatable cancer types. Dr. Thompson is being honored for his leadership role in the development of the AG-221 therapy for acute myeloid leukemia, which blocked the IDH1-2 enzyme’s disruption of normal cell maturation.
The SWCRF is a nonprofit organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research by funding research that identifies and corrects abnormal gene function that causes cancer. Since its inception in 1976, it has awarded approximately $100 million to support the work of more than 200 researchers across the globe. For more information, visit www. waxmancancer.org. ■
